A Platform for Specific Delivery of Lanthanide–Scandium Mixed-Metal Cluster Fullerenes into Target Cells
Version of Record online: 28 SEP 2012
Copyright © 2012 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Volume 1, Issue 5, pages 207–210, October 2012
How to Cite
Svitova, A., Braun, K., Popov, A. A. and Dunsch, L. (2012), A Platform for Specific Delivery of Lanthanide–Scandium Mixed-Metal Cluster Fullerenes into Target Cells. ChemistryOpen, 1: 207–210. doi: 10.1002/open.201200023
- Issue online: 17 OCT 2012
- Version of Record online: 28 SEP 2012
- Manuscript Received: 12 JUN 2012
- Funded Access
- molecular imaging;
- nitride cluster fullerenes
Lanthanides (Ln) find broad applications as contrast agents in medical imaging techniques such as magnetic resonance imaging (MRI).1 MRI is one of the most powerful, noninvasive imaging procedures, which is able to create images of tissues, organs and diseases in vivo.2, 3 Every year, about six million patients undergo MRI studies of which 30 % are performed using Gd-based contrast agents (CAs), which significantly reduce the spin-lattice relaxation time T1 of water protons leading to an increase of the signal intensity and improved contrast.4 Although medical applications of lanthanides in imaging are dominated by Gd3+, other lanthanides can be also used as MRI1, 5 CAs (e.g., Dy3+ is considered as an efficient contrast agent for high-field MRI6) and X-ray CAs.7, 8 Radioisotopes of lanthanides (especially 177Lu) are employed as therapeutic radiopharmaceuticals.9
Direct administration of Ln3+ ions in vivo is not possible because of their toxicity in the free ion form.10 In MRI, organic chelates of Gd3+ and other lanthanides are used to circumvent this problem.3, 11 The toxicity of Gd3+ is thus substantially decreased and its solubility in biological fluids is improved, albeit some negative phenomena still remain (e.g., fibrosis effects in kidneys12). The encapsulation of Ln3+ ions into the hollow carbon cages with formation of endohedral metallofullerenes (Ln-EMF) might be a more advantageous solution for a CAs,13 because (1) carbon cages protect Ln3+ ions against external chemical exposure and their release into the body, and (2) the water proton relaxivity r1 (the effect on 1/T1) of Ln-EMFs and especially Gd-EMFs is remarkably higher compared with organic chelates.14–16 Among the other potential medical applications of Ln-EMFs, their use as X-ray CAs8 or radiolabeling of Ln-EMFs for imaging and therapy can be mentioned.17, 18 Combination of different lanthanides, for example, Gd/Lu or Ho/Lu, in one EMF can be used for a design of multimodal contrast media.19
The distribution of standard CAs is usually restricted to the blood stream and the interstitial space. As a result, even contrast-enhanced imaging techniques still suffer from insufficient image resolution of morphological structures. The diagnostic problems, such as the limited possibility to exactly determine the actual tumor size and volume, to secure the metastases existence, and to distinguish the tumor tissues from healthy ones, have dramatic consequences for surgery and radiation therapy. The development of “molecular imaging” (MI) as an academic discipline has opened the way for further development in diagnostic imaging procedures.20 MI can be defined as imaging measurement of the cellular processes on the molecular level.21 The strategy is based on the targeting of specific proteins, in particular cells or cell parts, and coupling of this targeting with imaging techniques, which can be a promising way to enhance the contrast to differentiate between the tissues.
Reported applications of Ln-EMFs for imaging are mostly limited to the use of their water-soluble derivatives as standard nonspecific MRI agents. Their use for MI-related techniques is very rare, however available results show high potential of Ln-EMFs in MI.15, 16, 18 For instance, in vitro studies of a GdSc2N@C80-based BioShuttle system specifically designed to target human MDA-MB-231 breast adenocarcinoma cells showed that at a concentration of only 1/20 of the typical clinical dose, the sensitivity of this system was more than 500-fold higher than that of the commercial MRI-CA, Gd-DTPA (Gd-based complex with diethylene triamine pentaacetic acid), while a cell viability assay did not reveal any cell toxicity of the BioShuttle system.15
In this work, we introduce a Ln-EMF-based BioShuttle22, 23 system as a platform for intracellular delivery of Ln-EMFs into c-myc mRNA-expressing cells suitable as an MI and potentially a therapeutic agent. In particular, we describe a synthesis of MI probe c-myc-antisense-Gd@BioShuttle comprised of (1) a Gd-containing nitride cluster fullerene as an imaging component, (2) an address module (nuclear localization sequence), and (3) a transmembrane carrier peptide. Facile transport of this system into the target cells is demonstrated by in vitro studies.
Gd-containing mixed-metal cluster fullerenes were produced by the Krätschmer–Huffman method modified in our group.24 In this work, we used melamine (C3H6N6; organic base with high nitrogen content of 66 % by mass) as a new selective nitrogen source. The graphite rods packed with a Gd/Sc/graphite/melamine mixture were evaporated in 200 mbar helium atmosphere with a current of 100 A. MS data analysis of the fullerene extract showed formation of EMFs with the mixed-metal nitride clusters with the general formula GdxSc3−xN@C2n (x= 0–3, 39≤n≤44). Isolation of these mixed-metal nitride cluster fullerenes (NCFs) was accomplished by one-step HPLC. The analysis of the chromatogram and mass spectra proved the formation of NCFs as the major products of the reaction (Figure 1), which demonstrates the high selectivity of the synthesis using melamine as a nitrogen source (recently, similar selectivity was reported for urea25). The most abundant fraction eluting at a retention time (tR) of 29.8–32.0 min was collected and used for further synthesis of the modular contrast agent c-myc-antisense-Gd@BioShuttle (Figure 1 A). MS data analysis revealed that this fraction mainly consists of GdSc2N@C80 (I), Sc3N@C78, and Gd2ScN@C80 (I) (the ratio of the total ion currents corresponding to each molecule is 4:1.3:1, respectively), although trace amounts of Sc3N@C80, Sc4C2@C80 and GdSc2N@C78 are also seen in the mass spectrum (Figure 1 B). The relative yield of this fraction determined from the area of the HPLC peaks is 63 % of all endohedral fullerenes.
The structure of the c-myc-antisense-Gd@BioShuttle system is depicted in Figure 2 (detailed procedures for the synthesis of c-myc mRNA-targeted BioShuttle system and for conjugating the BioShuttle with Gd-EMF were described earlier,15, 22, 23, 26 and are briefly described in the Experimental Section). The BioShuttle complex consists of three functional components. The first component is a transport module consisting of a cell-penetrating peptide (CPP), an amphiphilic molecule responsible for the delivery of previously non-transportable molecules through biological membranes. This first part is connected via a disulfide bridge to a second part, which is the address component of the system. The address module comprises a peptide nucleic acid (PNA) directed against c-myc mRNA-expressing cells. C-myc mRNA is a template for the Myc protein, which is implicated in the rapid growth of cancer cells and is barely present in normal cells. In all c-myc-expressing cells, the PNA antisense sequence hybridizes with the c-myc mRNA (in the vicinity of c-myc exon II) providing high cell specificity. The hybrid remains in the cytoplasm of targeted cells together with the cargo module, which in this case is GdSc2N@C80 connected via a bridge to the address module. Thus, by its design, the BioShuttle system has high specificity, because of the trapping of the gadolinium fullerene as an MRI component into the neoplastic cells with an aberrant gene expression profile in contrast to normal cells that do not reveal hybridization possibilities.
To visualize the transport of the c-myc-antisense-Gd@BioShuttle system across biological membranes and its intracellular localization, confocal laser scanning microscopy (CLSM) measurements were performed. To perform CLSM studies, DU145 human prostate cancer cells were incubated with the c-myc-antisense-Gd@BioShuttle complex labeled with an Alexa Fluor® 546-conjugated fluorescent dye at the non-cleavable lysine-spacer site on the ε-amino group.22 In Figure 3, the intracellular localization of the c-myc-antisense-Gd@BioShuttle transporter after 5, 10, 20 and 30 min incubation time is illustrated via clear cytoplasmic fluorescence signals. Excitation was carried out at 543 nm (He/Ne laser), and the emission wavelength range was 572–650 nm.
In the first five minutes after incubation, the CLSM measurements showed a rapid accumulation of perinuclear fluorescence signal near the cell membrane, which gradually changed into a cytoplasm-localized signal after 30 min. This proves that the CA was transported into the cells with an aberrant c-myc gene expression profile. In contrast to the c-myc expressing cancer cells, no signal is detectable in normal cells because of the lack of mRNA/PNA hybridization (data not shown). Thus, the CLSM study demonstrates an effective transport of c-myc-antisense-Gd@BioShuttle complexes in human cancer cells showing the possibility of using this complex as an intracellular CA appropriate for an MI approach. It also can act as a suitable carrier system for diagnostic and therapeutic agents in cancer therapy.
In conclusion, Gd-containing nitride cluster fullerenes were synthesized as the main fullerene products at high relative yield using direct current (dc) arc discharge as the method and melamine as a new solid source of nitrogen. The mixed-metal cluster fullerenes GdxSc3−xN@C2n were introduced as a paramagnetic imaging module into the new c-myc-antisense-Gd@BioShuttle system. Facile intracellular transport and high specificity for cells that have an aberrant gene expression of a dye-labeled system was demonstrated by fluorescence spectroscopy. Thus, the Ln-EMF-BioShuttle concept can be used as a new molecular-imaging system with promising diagnostic and therapeutic medical applications.
Synthesis of fullerenes: The Krätschmer-Huffman synthesis was used. The graphite rods (length 100 mm, diameter 8 mm) were drilled, and the holes filled with a mixture gadolinium and scandium, graphite powder and melamine (C3H6N6) in the optimized ratio of Gd/Sc/C/N=1:1:15. The arc-discharge reactor for fullerene production consists of a water-cooled cylindrical chamber with two holders for graphite rods. A current of approx. 100 A was applied to evaporate the packed graphite rods in a 200 mbar helium atmosphere. The collected soot was first pre-extracted with acetone for 1 h to remove non-fullerene products like polycyclic aromatic hydrocarbons (PAH) and other low molecular structures. The fullerene mixture was then Soxhlet extracted by CS2 for 20 h. After the removal of CS2, the sample was redissolved in toluene. The isolation of mixed-metal nitride cluster fullerenes was accomplished by one-step HPLC using analytical Buckyprep columns (4.6×250 mm; Nacalai Tesque, Japan). The fraction eluting at tR=29.8–32.0 min was collected and subsequently characterized by MALDI-TOF MS with a Biflex III spectrometer (Bruker, Germany).
Synthesis of c-myc-antisense-Gd@BioShuttle system: The details of the synthetic procedures of the BioShuttle system were described earlier.23, 27 Briefly, the acid chloride of the fullerene was obtained by the method of Arrowsmith et al.28 For the synthesis of N-Boc-propyldiamin-tetrazin-dien, the acid chloride was suspended in abs CH2Cl2 (20 mL), and a mixture of N-Boc-1,3-diaminopropane (2 mmol) and Et3N (2 mmol) in the same solvent (10 mL) was added at 0–5 °C. The resulting solution was maintained at RT for 4 h, and the organic phase was washed with H2O, followed by 1 n HCl, and then again with H2O. The organic layer was dried over Na2SO4, filtered, and evaporated. The resulting residue was purified by column chromatography (silica gel, CHCl3/EtOH, 9:1). Sequences of single modules as well as the complete modular construct were purified by analytical HPLC (Shimadzu LC-8A, Duisburg, Germany) on a YMC ODS-A 7A S 7 µm reverse-phase column (20×250 mm). The fullerene(aminobonded)-tetrazoline-diene was obtained as follows. Monosubstituted tetrazinamine (0.5 mmol) and 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-trien-9-carboxylic acid chloride (0.5 mmol) were dissolved in CHCl3/Et3N (1:1, v/v) for 4 h at 0–5 °C. The solution was washed with H2O, followed by 1 n HCl, and then again with H2O. The organic layer was dried over Na2SO4, filtered, and evaporated. The residue was finally purified by HPLC (silica gel, CHCl3/EtOH, 9.5/0.5).
To perform the solid-phase peptide synthesis (SPPS) of peptide modules, we used a strategy described by Merrifield29 and Carpino,30 employing a fully automated synthesizer Syro II (MultiSyn Tech, Germany). The c-myc-antisense-Gd@BioShuttle conjugates were labeled with Alexa Fluor® 546 at the non-cleavable lysine-spacer site on the ε-amino group.
Cysteine groups of the cell-penetrating peptide (CPP) (transport module) and the peptide nucleic acid (PNA) (address module) with imaging component were oxidized at the range of 2 mg mL−1 in a 20 % DMSO/H2O solution, with the reaction reaching completion after 5 h. The progress of oxidation was monitored by analytical C18 reverse-phase HPLC.
Confocal laser scanning microscopy (CLSM) measurements: We used DU145 human prostate cancer cells that were characterized by Stone et al.31 The procedure of cell preparation was described earlier.32 Briefly, the cells were maintained in RPMI1640 medium (Gibco 11825) supplemented with fetal calf serum (FCS; 2 %; Gibco). The final BioShuttle concentration was 100 nM, and physiologic NaCl solution was used as a solvent. The studies and the control experiments were accomplished under identical conditions as detailed by Braun et al.22
We thank Frank Ziegs (IFW Dresden) for technical support.
- 9Comparative Evaluation of Therapeutic Radiopharmaceuticals, Technical Support Series No. 458, International Atomic Energy Agency (IAEA), Vienna, 2007.
- 10Am. J. Neuroradiol. 1983, 4, 1041–1042., , ,
- 13aGadolinium Endohedral Metallofullerene-Based MRI Contrast Agents by R. D. Bolskar in Medicinal Chemistry and Pharmacological Potential of Fullerenes and Carbon Nanotubes (Eds.: F. Cataldo, T. Da Ros), Springer Netherlands, 2008, pp. 157–180;
- 19Endohedral Metallofullerene Contrast Agents, United States Patent Application US/2006/0088474, 2006., ,
- 22dDrug Des. Devel. Ther. 2009, 2, 289–301., , , , , , , , , ,
- 27Diagnostic and/or Therapeutic Agent, Method for the Manufacture Thereof and Use Thereof, K. Braun, M. Bock, R. Pipkorn, W. Waldeck, M. Wiessler, B. Dedinger, J. Debus, V. Ehemann, L. Dunsch, (Leibniz Institute for Solid State and Materials Research, Dresden, Germany), PCT Patent Application EP 2009/064912, 2010.